EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment

Francesco Nucera, Paolo Ruggeri, Calogera Claudia Spagnolo, Mariacarmela Santarpia, Antonio Ieni iD, Francesco Monaco, Giovanni Tuccari iD, Giovanni Pioggia iD, Sebastiano Gangemi

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25126685 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Francesco Nucera und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF), Università degli Studi di Messi…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, MicroRNAs, Lung Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer (LC) is one of the most prevalent cancers in both men and women and today is still characterized by high mortality and lethality. Several biomarkers have been identified for evaluating the prognosis of non-small cell lung cancer (NSCLC) patients and selecting the most effective therapeutic strategy for these patients. The introduction of innovative targeted therapies and immunotherapy with immune checkpoint inhibitors (ICIs) for the treatment of NSCLC both in advanced stages and, more recently, also in early stages, has revolutionized and significantly improved the therapeutic scenario for these patients. Promising evidence has also been shown by analyzing both micro-RNAs (miRNAs) and the lung/gut microbiota. MiRNAs belong to the large family of non-coding RNAs and play a role in the modulation of several key mechanisms in cells such as proliferation, differentiation, inflammation, and apoptosis. On the other hand, the microbiota (a group of several microorganisms found in human orgasms such as the gut and lungs and mainly composed by bacteria) plays a key role in the modulation of inflammation and, in particular, in the immune response. Some data have shown that the microbiota and the related microbiome can modulate miRNAs expression and vice versa by regulating several intracellular signaling pathways that are known to play a role in the pathogenesis of lung cancer. This evidence suggests that this axis is key to predicting the prognosis and effectiveness of ICIs in NSCLC treatment and could represent a new target in the treatment of NSCLC. In this review, we highlight the most recent evidence and data regarding the role of both miRNAs and the lung/gut microbiome in the prediction of prognosis and response to ICI treatment, focusing on the link between miRNAs and the microbiome. A new potential interaction based on the underlying modulated intracellular signaling pathways is also shown.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungMicroRNAsLung NeoplasmsImmune Checkpoint InhibitorsHumansMicrobiotaGastrointestinal MicrobiomePrognosisBiomarkers, TumorGene Expression Regulation, NeoplasticAnimals

Stichwörter der Autor:innen

ICI treatmentNSCLCbiomarkerslung/gut microbiotamiRNAs

Substanzen

MicroRNAsImmune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF), Università degli Studi di Messina, 98166 Messina, Italy.
  • Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, 98122 Messina, Italy.
  • Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", Section of Anatomic Pathology, University of Messina, 98100 Messina, Italy.
  • Chirurgia Toracica, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF), Università degli Studi di Messina, 98166 Messina, Italy.
  • Institute for Biomedical Research and Innovation (IRIB), National Research Council of Italy (CNR), 98164 Messina, Italy.
  • Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria 1, 98125 Messina, Italy.

ORCID-Profile: Antonio Ieni, Giovanni Tuccari, Giovanni Pioggia

Zitieren

APA

Nucera, F., Ruggeri, P., Spagnolo, C. C., Santarpia, M., Ieni, A., Monaco, F., Tuccari, G., Pioggia, G., & Gangemi, S. (2024). MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126685

Vancouver

Nucera F, Ruggeri P, Spagnolo CC, Santarpia M, Ieni A, Monaco F, et al. MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126685

BibTeX
@article{Nucera2024,
  author = {Nucera, Francesco and Ruggeri, Paolo and Spagnolo, Calogera Claudia and Santarpia, Mariacarmela and Ieni, Antonio and Monaco, Francesco and Tuccari, Giovanni and Pioggia, Giovanni and Gangemi, Sebastiano},
  title = {MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25126685}
}
Kostenlos starten →